Tripeptide tyroserleutide plus doxorubicin: Therapeutic synergy and side effect attenuation

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Zhu, Zhi Feng ^a   Chen, Li Juan ^a   Lu, Rong ^a,b   Jia, Jing ^a   Liang, Yu ^a   Xu, Qiong ^a   Zhou, Chun Lei ^a   Wang, Li ^a   Wang, Song ^a   Yao, Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Shenzhen Kangzhe Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HEMOGLOBIN; SODIUM CHLORIDE; TRIPEPTIDE DERIVATIVE; TYROSERLEUTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; H TYR SER LEU OH; H-TYR-SER-LEU-OH; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHERMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NEPHROTOXICITY; NONHUMAN; NUDE MOUSE; SURVIVAL TIME; TUMOR VOLUME; WEIGHT REDUCTION; ANIMAL; DRUG SCREENING; LIVER TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; OLIGOPEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57849102975     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-342     Document Type: Article

References (23)

1. Yang JL Wang Q Wu ZY Li X Wang YP The effect of genistein on the proliferation of human hepatoceUular carcinoma cell SMMC-7721 Chinese Journal of Hepatology 2006, 08:622-623
2. Ganey PE Carter LS Mueller RA Thurman RG Doxorubicin toxicity in perfused rat heart. Decreased cell death at low oxygen tension Circ Res 1991, 68:1610-1613 2036713
3. Yao Z Lu R Jia J Zhao P Yang J Zheng M Lu J Jin M Yang H Gao W The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma Peptides 2006, 27:1167-1172 10.1016/ j.peptides.2005.02.026 16129512
4. Lu R Jia J Bao L Fu Z Li G Wang S Wang Z Jin M Gao W Yao Z Experimental study of the inhibition of human hepatocarcinoma BEL-7402 cells by the tripeptide tyroserleutide(YSL) Cancer Chemother Pharmacol 2006, 57:248-256 10.1007/s00280-005-0046-z 16028100
5. Han R Anticancer drugs research and exoeriment technology Beijing: Beijing Medical University and Peking Union Medical College association publishing company 1997.
6. Volm M Faufmann M MAttern J Wayss K Sensitivity tests of tumors to cytostatic agents. I. Comparative investigations on transplanted tumors in vivo and in vitro Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1975, 83:85-96 124519
7. Igawa M Kadena H Ueda M Usui T Association between patient characteristics and treatment history, and toxicity associated with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced urothelial cancer Br J Urol 1994, 73:263-267 10.1111/ j.1464-410X.1994.tb07515.x 8162503
8. Zeidán Q Strauss M Porras N Anselmi G Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection J Submicrosc Cytol Pathol 2002, 34:315-321 12408365
9. Di Donato A Ghiggeri GM Di Duca M Jivotenko E Acinni R Campolo J Ginevri F Gusmano R Lysyl oxidase expression and collagen cross-linking during chronic adriamycin nephropathy Nephron 1997, 76:192-200 10.1159/ 000134547 9200411
10. Singal PK Deally CM Weinberg LE Subcellular effects of adriamycin in the heart: A concise review J Mol Cell Cardiol 1987, 19:817-828 10.1016/ S0022-2828(87)80392-9 3320376
11. Lefrak EA Pitha J Rosenheim S Gottlieb JA A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 1973, 32:302-314 10.1002/ 1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2 4353012
12. Weil-Hillman G Uckun FM Manske JM Vallera DA Combined immunochemotherapy of human solid tumors in nude mice Cancer Res 1987, 47:579-585 3491678
13. Boehmer S Luszczynska A Schwarzer R Coping and quality of life after tumor surgery: Personal and social resources promote different domains of quality of life Anxiety Stress Coping 2007, 20:61-75 10.1080/ 10615800701195439 17999215
14. Schmitt M Harbeck N Daidone MG Brynner N Duffy MJ Foekens JA Sweep FC Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: Tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer Int J Oncol 2004, 25:1397-1406 15492831
15. Poulakis V Skriapas K de Vries R Dillenburg W Ferakis N Witzsch U Becht E Quality of life after laparoscopic and open retroperitoneal lymph node dissection in clinical Stage I nonseminomatous germ cell tumor: A comparison study Urology 2006, 68:154-160 10.1016/j.urology.2006.01.023 16820195
16. Bampoe J Ritvo P Bernstein M Quality of life in patients with brain tumor: What's relevant in our quest for therapeutic efficacy Neurosurg Focus 1998, 4:e6 10.3171/foc.1998.4.6.9 17154446
17. Shaw EG Rosdhal R D'Agostino RB Jr Lovato J Naughton MJ Robbins ME Rapp SR Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life J Clin Oncol 2006, 24:1415-1420 10.1200/JCO.2005.03.3001 16549835
18. Liao ZJ Modern oncotherapy De material medica Xi'an: World Publishing Corporation; 2002.
19. Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 1990, 25:286-290 10.1007/BF00684887 2295114
20. Lu R Jia J Bao L Fu Z Li G Wang S Wang Z Jin M Gao W Yao Z Experimental study of the inhibition of human hepatocellular carcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL) Cancer Chemother Pharmacol 2006, 57:248-256 10.1007/s00280-005-0046-z 16028100
21. Xu LH Deng CS Zhu YQ Liu SQ Liu DZ Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480 World J Gastroenterol 2003, 9:1241-1245 12800232
22. Lin XY Zhou GY Song YH Gao P Sun YL PTEN inhibits cell growth and increases chemosensitivity to doxorubicin of human breast cancer cells Chinese J General Surgery 2005, 20:240-242
23. Hoke EM Maylock CA Shacter E Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin Free Radic Biol Med 2005, 39:403-411 10.1016/j.freeradbiomed.2005.03.029 15993339